Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) 70.0% LOWER; announced that DYNAMO, a registration-focused Phase 2 monotherapy study evaluating the efficacy and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE